Arrowstreet Capital Limited Partnership Trims Position in Encompass Health Co. (NYSE:EHC)

Arrowstreet Capital Limited Partnership lowered its position in Encompass Health Co. (NYSE:EHC) by 4.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,094,570 shares of the company’s stock after selling 48,572 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 1.09% of Encompass Health worth $101,084,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB grew its stake in shares of Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after buying an additional 137 shares during the period. CBIZ Investment Advisory Services LLC grew its position in Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after acquiring an additional 127 shares during the period. Tompkins Financial Corp acquired a new stake in Encompass Health during the fourth quarter worth $46,000. V Square Quantitative Management LLC raised its position in Encompass Health by 43.8% in the fourth quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock valued at $54,000 after purchasing an additional 177 shares during the period. Finally, Signaturefd LLC lifted its stake in shares of Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company’s stock valued at $65,000 after purchasing an additional 125 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.10% of the stock is owned by insiders.

Encompass Health Price Performance

Shares of NYSE EHC opened at $101.40 on Tuesday. The stock’s 50-day moving average is $98.81 and its two-hundred day moving average is $97.52. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The company has a market cap of $10.21 billion, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 2.31 and a beta of 0.92. Encompass Health Co. has a 1-year low of $78.53 and a 1-year high of $104.55.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Analysts forecast that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.67%. The ex-dividend date is Tuesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is presently 15.25%.

Analyst Upgrades and Downgrades

EHC has been the topic of several research analyst reports. Barclays boosted their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. KeyCorp upped their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, February 15th. Finally, William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.